NeuroPace (NASDAQ:NPCE) Price Target Raised to $16.00

NeuroPace (NASDAQ:NPCE) had its price target hoisted by Wells Fargo & Company from $15.00 to $16.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

NPCE has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price objective on shares of NeuroPace in a report on Wednesday. Leerink Partners restated an “outperform” rating and issued a $19.00 target price on shares of NeuroPace in a research note on Wednesday. Finally, Zacks Research cut NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

NeuroPace Stock Up 2.7%

Shares of NASDAQ:NPCE opened at $13.12 on Wednesday. NeuroPace has a 1 year low of $6.63 and a 1 year high of $18.98. The company has a market capitalization of $437.00 million, a PE ratio of -17.26 and a beta of 1.90. The business has a fifty day moving average price of $10.37 and a two-hundred day moving average price of $10.87. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 4.51.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. The company had revenue of $27.35 million for the quarter, compared to the consensus estimate of $24.64 million. NeuroPace has set its FY 2025 guidance at EPS. Analysts forecast that NeuroPace will post -1 earnings per share for the current year.

Institutional Investors Weigh In On NeuroPace

Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. grew its position in shares of NeuroPace by 83.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after purchasing an additional 1,118 shares in the last quarter. Legal & General Group Plc boosted its stake in NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP bought a new position in NeuroPace in the 2nd quarter worth about $35,000. Police & Firemen s Retirement System of New Jersey grew its holdings in NeuroPace by 72.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock valued at $71,000 after buying an additional 2,668 shares in the last quarter. Finally, AlphaQuest LLC bought a new stake in shares of NeuroPace during the second quarter valued at about $82,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.